Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
Total Valuation
Design Therapeutics has a market cap or net worth of $164.04M. The enterprise value is $53.07M.
Market Cap$164.04M
Enterprise Value$53.07M
Share Statistics
Design Therapeutics has 56.76M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56.76M
Owned by Insiders19.58%
Owned by Instutions30.69%
Financial Efficiency
Design Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -25.61%.
Return on Equity (ROE)-20.48%
Return on Assets (ROA)-19.67%
Return on Invested Capital (ROIC)-25.61%
Return on Capital Employed (ROCE)-25.61%
Revenue Per Employee$0
Profits Per Employee-$918,296.296
Employee Count54
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Design Therapeutics is -7.04. Design Therapeutics’s PEG ratio is 0.27.
PE Ratio-7.04
PS Ratio0.00
PB Ratio1.44
Price to Fair Value1.44
Price to FCF-8.04
Price to Operating Cash Flow-8.10
PEG Ratio0.27
Income Statement
In the last 12 months, Design Therapeutics had revenue of $0.00 and earned -$49.59M in profits. Earnings per share was -$0.88.
Revenue$0.00
Gross Profit-$294.00K
Operating Income-$62.38M
Pretax Income-$49.59M
Net Income-$49.59M
EBITDA-61.79M
Earnings Per Share (EPS)-0.88
Cash Flow
In the last 12 months, operating cash flow was -$43.10M and capital expenditures -$340.00K, giving a free cash flow of -$43.45M billion.
Operating Cash Flow-$43.10M
Free Cash Flow-$43.45M
Free Cash Flow per Share-$0.77
Dividends & Yields
Design Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-12.44%
Earnings Yield-14.20%
Stock Price Statistics
Beta2.06
52-Week Price Change-23.75%
50-Day Moving Average4.36
200-Day Moving Average4.98
Relative Strength Index (RSI)32.45
Average Volume (3m)158.26K
Important Dates
Design Therapeutics upcoming earnings date is May 12, 2025, After Close.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Design Therapeutics as a current ratio of 29.31, with Debt / Equity ratio of <0.01
Current Ratio29.31
Quick Ratio29.31
Debt to Market Cap<0.01
Net Debt to EBITDA0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Design Therapeutics has paid $99.72K in taxes.
Income Tax$99.72K
Effective Tax Rate0.00%
Enterprise Valuation
Design Therapeutics EV to EBITDA ratio is -5.26, with an EV/FCF ratio of -7.55.
EV to Sales0.00
EV to EBITDA-5.26
EV to Free Cash Flow-7.55
EV to Operating Cash Flow-7.61
Balance Sheet
Design Therapeutics has $245.48M in cash and marketable securities with $2.33M in debt, giving a net cash position of -$243.14M billion.
Cash & Marketable Securities$245.48M
Total Debt$2.33M
Net Cash-$243.14M
Net Cash Per Share-$4.28
Tangible Book Value Per Share$4.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Design Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$5.00
Price Target Upside73.01%
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast26.63%